Both parties will create a next-generation AIGC-driven antibody drug discovery platform jointly and promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.

Learn MoreBioGeometry Joins Hands with Sanyou to Build a New Generation AIGC-Driven Antibody Drug Discovery Platform